Tower Research Capital LLC TRC grew its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) by 411.3% during the 4th quarter, HoldingsChannel reports. The fund owned 8,800 ...
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today ...
CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the ...
--Cullinan Therapeutics, Inc., a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its management team will host a company event at the 2025 ...
Cullinan plans to share updated efficacy and safety data in patients previously treated with amivantamab during a mini oral abstract session at the IASLC 2025 WCLC.
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of ...
American Century Companies Inc. raised its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) by 11.0% during the 4th quarter, Holdings Channel reports. The institutional ...
About Cullinan Therapeutics Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients.
--Cullinan Therapeutics, Inc., a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment of Mary Kay Fenton as Chief Financial Officer, beginning ...
Our AI model demonstrates 28% historical accuracy for CGEM predictions, based on advanced machine learning algorithms trained on over 10 years of market data.